Search research articles
Contact Us
Filters
Showing results (1-10 of 114) with videos related to
Page
of 12
Sort By:
The New England Journal of Medicine
|
August 24, 2022
Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply
David C Fajgenbaum
Hematology. American Society of Hematology. Education Program
|
December 4, 2018
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
David C Fajgenbaum
Blood
|
November 30, 2018
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
David C Fajgenbaum
Advances in Experimental Medicine and Biology
|
August 8, 2024
The Cytokine Storm of Multicentric Castleman Disease
David C Fajgenbaum
Current Opinion in Rheumatology
|
July 15, 2021
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate
Puja Mehta, David C Fajgenbaum
Blood
|
February 28, 2020
Overview of Castleman disease
Angela Dispenzieri, David C Fajgenbaum
Immunotherapy
|
December 5, 2015
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease
David C Fajgenbaum, Razelle Kurzrock
Hematology/Oncology Clinics of North America
|
November 22, 2017
Castleman Disease Pathogenesis
David C Fajgenbaum, Dustin Shilling
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy
Sally Nijim, David C Fajgenbaum
Clinical Advances in Hematology & Oncology : H&O
|
September 20, 2022
How we manage idiopathic multicentric Castleman disease
Joshua D Brandstadter, David C Fajgenbaum
Page
of 12
Search research articles
Search
Showing results (1-10 of 114) with videos related to
Sort By:
Page
of 12
The New England Journal of Medicine
|
August 24, 2022
Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply
David C Fajgenbaum
Hematology. American Society of Hematology. Education Program
|
December 4, 2018
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
David C Fajgenbaum
Blood
|
November 30, 2018
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
David C Fajgenbaum
Advances in Experimental Medicine and Biology
|
August 8, 2024
The Cytokine Storm of Multicentric Castleman Disease
David C Fajgenbaum
Current Opinion in Rheumatology
|
July 15, 2021
Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate
Puja Mehta, David C Fajgenbaum
Blood
|
February 28, 2020
Overview of Castleman disease
Angela Dispenzieri, David C Fajgenbaum
Immunotherapy
|
December 5, 2015
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease
David C Fajgenbaum, Razelle Kurzrock
Hematology/Oncology Clinics of North America
|
November 22, 2017
Castleman Disease Pathogenesis
David C Fajgenbaum, Dustin Shilling
Hematology. American Society of Hematology. Education Program
|
December 7, 2024
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy
Sally Nijim, David C Fajgenbaum
Clinical Advances in Hematology & Oncology : H&O
|
September 20, 2022
How we manage idiopathic multicentric Castleman disease
Joshua D Brandstadter, David C Fajgenbaum
Page
of 12